A2Z-TIMI 21

A to Z-(TIMI 21) evaluated if early aggressive treatment with simvastatin compared to standard therapy reduces major cardiac events at 1 year in high-risk acute coronary syndrome patients. TIMI 21 also evaluated the safety and efficacy of enoxaparin compared to unfractionated heparin when given to patients with acute coroanry syndromes also receiving the GP IIb/IIIa inhibitor tirofiban.

PRESENTATIONS

TIMI 21 Slides

PUBLICATIONS

Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials)

Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial

A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22

The safety and efficacy of achieving very low LDL-cholesterol concentrations with high dose statin therapy

Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial

Evaluation of the National Cholesterol Education Program Adult Treatment Panel III algorithm for selecting candidates for statin therapy: insights from the A to Z trial

Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease

Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial

Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial

Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial

The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy

 

 

%d bloggers like this:
search previous next tag category expand menu location phone mail time cart zoom edit close